Bicycle Therapeutics Files 8-K
Ticker: BCYC · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1761612
Sentiment: neutral
Topics: filing, regulatory
Related Tickers: BCYC
TL;DR
BCYC filed an 8-K, mostly procedural stuff, no major news.
AI Summary
On December 13, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific new financial figures or material events detailed in the provided text. The report confirms the company's identity and filing status.
Why It Matters
This 8-K filing serves as a routine update for investors, confirming the company's reporting status and providing a point of reference for any future disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information indicating significant new risks or changes in the company's financial or operational status.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- 0001761612 (company) — Central Index Key
- 001-38916 (company) — SEC File Number
- December 13, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Bicycle Therapeutics plc?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of December 13, 2024.
What is the Central Index Key (CIK) for Bicycle Therapeutics plc?
The Central Index Key for Bicycle Therapeutics plc is 0001761612.
What is the SEC File Number for Bicycle Therapeutics plc?
The SEC File Number for Bicycle Therapeutics plc is 001-38916.
On what date was this 8-K report filed?
This 8-K report was filed on December 13, 2024.
What jurisdiction is Bicycle Therapeutics plc incorporated in?
Bicycle Therapeutics plc is incorporated in England and Wales.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-12-13 09:15:53
Filing Documents
- tm2430827d1_8k.htm (8-K) — 29KB
- tm2430827d1_ex99-1.htm (EX-99.1) — 29KB
- tm2430827d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-128241.txt ( ) — 289KB
- bcyc-20241213.xsd (EX-101.SCH) — 3KB
- bcyc-20241213_def.xml (EX-101.DEF) — 26KB
- bcyc-20241213_lab.xml (EX-101.LAB) — 36KB
- bcyc-20241213_pre.xml (EX-101.PRE) — 25KB
- tm2430827d1_8k_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On December 12, 2024, Bicycle Therapeutics plc (the "Company") issued a press release announcing data updates across the zelenectide pevedotin program and its development strategy leveraging NECTIN4 gene amplification. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference. On December 13, 2024, the Company hosted a conference call and webcast to review the data updates for zelenectide pevedotin. The webcast and a copy of the presentation used in the conference call can be accessed by visiting the "Presentation + Events" section at investors.bicycletherapeutics.com.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (a) Exhibits 99.1 Press Release dated December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 13, 2024 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer